This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Tej Quine virtually assessed pathway (VAP) clinic
Indications:1
Advanced breast cancer (aBC)
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).
In pre- or perimenopausal women, the ET should be combined with a luteinising hormone-releasing hormone (LHRH) agonist
Early breast cancer (eBC)
KISQALI in combination with an AI, is indicated for the adjuvant treatment of patients with HR+/HER2– eBC at high risk of recurrence (see section 5.1 of the SmPC for eligibility criteria)
In pre/perimenopausal women, or in men, the AI should be combined with an LHRH agonist
KISQALI is not recommended to be used in combination with tamoxifen.
For information on the safety profile of KISQALI in aBC click here, and for eBC, click here.
Please consult your local SmPC for the full KISQALI safety and tolerability profile.
Click the play button below to watch the video from Tej Quine
Join Tej Quine as she delves into the VAP service, exploring how it can facilitate clinical prioritisation and the impact this service had on patient satisfaction.
VIDEO
aBC, advanced breast cancer; AI, aromatase inhibitor; eBC, early breast cancer; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; VAP, virtually assessed pathway; SmPC, summary of product characteristics.
Reference
KISQALI® (ribociclib) Summary of Product Characteristics.
UK | October 2025 | FA-11523903
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.